Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.690
+0.070 (4.32%)
At close: Jan 16, 2026, 4:00 PM EST
1.710
+0.020 (1.18%)
After-hours: Jan 16, 2026, 7:56 PM EST
Ocugen Revenue
Ocugen had revenue of $1.75M in the quarter ending September 30, 2025, with 54.23% growth. This brings the company's revenue in the last twelve months to $5.37M, up 14.26% year-over-year. In the year 2024, Ocugen had annual revenue of $4.06M, down -32.82%.
Revenue (ttm)
$5.37M
Revenue Growth
+14.26%
P/S Ratio
92.79
Revenue / Employee
$56,526
Employees
95
Market Cap
527.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.06M | -1.98M | -32.82% |
| Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
| Dec 31, 2022 | 2.49M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 43.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 8.00K | -18.00K | -69.23% |
| Dec 31, 2012 | 26.00K | -97.00K | -78.86% |
| Dec 31, 2011 | 123.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OCGN News
- 2 days ago - Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript - Seeking Alpha
- 2 days ago - Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
- 2 days ago - Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 4 days ago - Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - GlobeNewsWire
- 5 days ago - Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy - GlobeNewsWire
- 8 days ago - Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference - GlobeNewsWire
- 12 days ago - Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments - Seeking Alpha
- 5 weeks ago - Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - GlobeNewsWire